AbstractObjective To evaluate the clinical efficacy and prognostic factors of recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery. Methods From December 2011 to December 2015,152 cases of recurrent thoracic esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery were retrospectively analyzed. The overall survival (OS) after treatment failure, clinical efficacy and prognostic factors of different salvage treatments were analyzed. OS was calculated by Kaplan-Meier method. Prognostic analysis was performed by using multivariate Cox regression model. Results The median interval of the first recurrence was 10.6(2.0 to 69.1) months. The median OS after recurrence was 8.0(0.8 to 43.3) months. The 1-, 2-and 3-year OS rates after recurrence were 36.0%,15.1% and 5.2%,respectively. The median OS of patients with locoregional recurrence alone, distant metastasis alone and locoregional recurrence combined with distant metastasis was 11.3(1.8 to 43.3) months,6.7(1.2 to 28.6) months and 5.1(0.8 to 22.9) months, respectively. Multivariate analysis demonstrated that neoadjuvant chemotherapy (P=0.009), ypTNM stage (P=0.012), comprehensive treatment after recurrence (P=0.000) and locoregional recurrence (P=0.026) were independently correlated with the OS of patients with recurrent esophageal squamous cell carcinoma. Conclusion s Neoadjuvant therapy, ypTNM stage, recurrence pattern and post-recurrence treatment are the independent risk factors for clinical prognosis of patients with recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery. Clinical prognosis of patients with recurrent esophageal squamous cell carcinoma after neoadjuvant therapy is not satisfactory. After recurrence, combined treatment mode should be adopted according to the site of recurrence and neoadjuvant treatment mode to maximize the benefits of salvage treatment.
Corresponding Authors:
Ge Hong,Email:gehong666@126.com
Cite this article:
Fan Chengcheng,Feng Zhuo,Ge Hong et al. Prognostic analysis of recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgical treatment[J]. Chinese Journal of Radiation Oncology, 2020, 29(1): 26-30.
Fan Chengcheng,Feng Zhuo,Ge Hong et al. Prognostic analysis of recurrent esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgical treatment[J]. Chinese Journal of Radiation Oncology, 2020, 29(1): 26-30.
[1]Meredith KL,Weber JM,Turaga KK,et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer[J]. Ann Surg Oncol,2010,17(4):1159-1167. DOI:10.1245/s10434-009-0862-1.
[2]van Hagen P,Hulshof MC,van Lanschot JJ,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med,2012,366(22):2074-2084. DOI:10.1056/NEJMoa1112088.
[3]Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J]. Lancet Oncol,2011,12(7):681-692. DOI:10.1016/S1470-2045(11)70142-5.
[4]Blom RL,Lagarde SM,van Oudenaarde K,et al. Survival after recurrent esophageal carcinoma has not improved over the past 18 years[J]. Ann Surg Oncol,2013,20(8):2693-2698. DOI:10.1245/s10434-013-2936-3.
[5]Dresner SM,Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy[J]. Br J Surg,2000,87(10):1426-1433. DOI:10.1046/j.1365-2168.2000.01541.x.
[6]Abate E,DeMeester SR,Zehetner J,et al. Recurrence after esophagectomy for adenocarcinoma:defining optimal follow-up intervals and testing[J]. J Am Coll Surg,2010,210(4):428-435. DOI:10.1016/j.jamcollsurg.2010.01.006.
[7]Butter R,Lagarde SM,van Oijen MGH,et al. Treatment strategies in recurrent esophageal or junctional cancer[J]. Dis Esophagus,2017,30(9):1-9. DOI:10.1093/dote/dox082.
[8]Parry K,Visser E,van Rossum PS,et al. Prognosis and treatment after diagnosis of recurrent esophageal carcinoma following esophagectomy with curative intent[J]. Ann Surg Oncol,2015,22 Suppl 3:S1292-1300. DOI:10.1245/s10434-015-4840-5.
[9]Ninomiya I,Okamoto K,Tsukada T,et al. Recurrence patterns and risk factors following thoracoscopic esophagectomy with radical lymph node dissection for thoracic esophageal squamous cell carcinoma[J]. Mol Clin Oncol,2016,4(2):278-284. DOI:10.3892/mco.2015.688.
[10]Blackham AU,Sm HN,Schell MJ,et al. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer[J]. J Surg Oncol,2018,117(2):150-159. DOI:10.1002/jso.24808.
[11]Miyata H,Yamasaki M,Kurokawa Y,et al. Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas[J]. Ann Surg Oncol,2011,18(12):3353-3361. DOI:10.1245/s10434-011-1747-7.
[12]Sugiyama M,Morita M,Yoshida R,et al. Patterns and time of recurrence after complete resection of esophageal cancer[J]. Surg Today,2012,42(8):752-758. DOI:10.1007/s00595-012-0133-9.
[13]Butter R,Lagarde SM,Mgh VO,et al. Treatment strategies in recurrent esophageal or junctional cancer[J]. Dis Esophagus,2017,30(9):1-9. DOI:10.1093/dote/dox082.
[14]Salah-Eddin AB,Claudia P,Nils H,et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer:a randomised trial of the arbeitsgemeinschaft internistische onkologie (FLOT65+)[J]. Eur J Cancer,2013,49(4):835-842. DOI:10.1016/j.ejca.2012.09.025.
[15]Taniyama Y,Sakurai T,Hikage M,et al. How does presurgical chemotherapy influence the efficiency of treatment for esophageal cancer recurrence after curative esophagectomy?[J]. Thorac Cancer,2019,10(4):769-774. DOI:10.1111/1759-7714.12996.
[16]Mariette C,Balon JM,Piessen G,et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease[J]. Cancer,2003,97(7):1616-1623. DOI:10.1002/cncr.11228.
[17]Su XD,Zhang DK,Zhang X,et al. Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma[J]. J Thorac Dis,2014,6(7):949-957. DOI:10.3978/j.issn.2072-1439.2014.07.14.
[18]Kato H,Fukuchi M,Miyazaki T,et al. Classification of recurrent esophageal cancer after radical esophagectomy with two-or three-field lymphadenectomy[J]. Anticancer Res,2005,25(5):3461-3467.
2020, Vol. 29 
